Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033047 | 0.84 | CYP11B1 (0.49) | KDM4ECYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1035431 | 0.82 | EGLN1 (0.54) | LMNAKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1033354 | 0.81 | PARP1 (0.60) | KMODHODHLMNAKDM4EHTT | |
| SCHEMBL1035668 | 0.80 | CYP1A2 (0.55) | LMNAKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1035756 | 0.79 | CYP1A2 (0.55) | LMNAHTTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11782258 | 0.78 | MKNK1 (0.55) | KMODHODHLMNAKDM4EHTT | |
| SCHEMBL1034289 | 0.78 | NPC1 (0.50) | LMNAKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6760390 | 0.77 | LMNA (0.57) | KMOLMNAMKNK1MKNK2CYP1A2 | |
| SCHEMBL3229462 | 0.77 | ALDH1A1 (0.53) | KMODHODHLMNAKDM4EHTT | |
| SCHEMBL6016346 | 0.77 | KMT2A (0.56) | KMODHODHLMNAHTTMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083438-B | The quinoline of conditioning agent and related analogs as silent message regulatory factor | 西特里斯药业公司 | 2016-11-09 | — | — | CN | disclosed |
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| CN-102083438-A | Quenolines and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-06-01 | — | — | CN | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2273992-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | KMO 256/4885DHODH 1011/4885LMNA 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.